partnerships

Transform tomorrow, be our partner

Over time we have established partnerships with companies that seek to further the progress of immunostimulants and cancer therapies, as well as with some of the principal Brazilian universities, in the development of vaccines against infectious diseases.

We are open to forming further strategic partnerships in the areas of human and veterinary medicine with academic groups and biotechnology companies in Latin America, principally for the creation of new Hiltonol^®-containing vaccines.

We have GMP clinical material available for use in clinical trials and pre-clinical material suitable for pre-clinical and scientific experimentation.

Are you interested?

Enter in contact by e-mail with contato@orygen.com.br to explore and discuss possible collaborative opportunities.

Our key partnerships

Find out details of the work we are carrying out in very successful partnerships.

In 2018, we entered into an international partnership with the renowned American biotechnology company Oncovir, to develop the immunostimulant Hiltonol^®.

Our mission is to bring this exclusive innovation to Brazil and other Latin American countries, including Mexico, with exclusive rights for commercialization, whether for isolated use or for co-development of new vaccines to increase their effectiveness. Orygen’s role is in the manufacture of Hiltonol^® in collaboration with Eurofarma.

Created in 2012, CT Vacinas is a center for biotechnological research that is the result of a partnership between the Universidade Federal de Minas Gerais (UFMG), the Instituto René Rachou of the Fundação Oswaldo Cruz (Fiocruz-Minas) and the Parque Tecnológico de Belo Horizonte (BH-TEC). Currently the Center is focused on the development of novel technologies for the production of diagnostic kits and vaccines against human and veterinary diseases. It played a fundamental role in combating Covid-19 through the generation of a new vaccine and diagnostic tests. Orygen maintains an ongoing collaboration with CT Vacinas studying the use of Hiltonol^® in prophylactic and therapeutic vaccines against chronic infectious diseases.

Universidades

Estamos colaborando com cientistas renomados da USP, UFMG, UFOP e UFRJ no desenvolvimento de vacinas revolucionárias. Da Covid-19 à leishmaniose, malária e a doença de Chagas, aplicarmos os benefícios do Hiltonol^® em diversas áreas de saúde pública e animal. Em 2023, adquirimos os direitos de manufatura do Hiltonol^® no Brasil em colaboração com a Eurofarma para a montagem do processo de manufatura do imunoestimulante. Estamos ansiosos para o futuro, onde planejamos ensaios clínicos em humanos para vacinas vitais contra a Doença de Chagas e leishmaniose, além de discutir possíveis ensaios clínicos para o tratamento do câncer de próstata com o Hiltonol^®.

Partnerships

Our key partnerships

In 2018, we entered into an international partnership with the renowned American biotechnology company Oncovir, to develop the immunostimulant Hiltonol®.

Universidades

In 2018, we entered into an international partnership with the renowned American biotechnology company Oncovir, to develop the immunostimulant Hiltonol^®.